Axovant spinoff Arvelle Therapeutics received $180m in the LSP-led series A round, and will focus on the development of a recently licensed epilepsy drug.
Life sciences investment firm LSP has confirmed it has led a $180m series A round for Arvelle Therapeutics, a Switzerland-based epilepsy drug developer spun off from pharmaceutical company Axovant.
Andera Partners, BRV Capital Management, NovaQuest and HIG BioHealth Partners also participated in the round. The company had initially revealed that it had raised more than $100m without giving a precise figure, and Axovant will carry a 5% stake in the company forward.
Arvelle is developing drug therapies to treat…
